Study of SynKIR-110 Autologous T cells Transduced with

Recruiting

18 years - 99 years

All

Phase 1

10 participants needed

1 Location

Brief description of study

This study involves research of an investigational therapy called SynKIR-110. SynKIR-110 is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells (white blood cells that are a part of the immune system) are changed in a laboratory so they can attack cancer cells. The purpose of this research study is to identify a safe dose of SynKIR-110 in patients with advanced Ovarian cancer, Cholangiocarcinoma (bile duct cancer) or Mesothelioma (a tumor of the tissue that lines the lungs, stomach, heart, and other organs).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Ovarian Cancer, Cholangiocarcinoma, Mesothelioma
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 852470

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study of SynKIR-110 Autologous T cells Transduced with Mesothelin KIR-CAR in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer Cholangiocarcinoma or Mesothelioma

Brief description of study

Eligibility of study

Find a site

Interested in the study